Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Bendamustine in Relapsed/Refractory CLL
NCT01131247Phase 2Withdrawn
- Sponsor
- Nevada Cancer Institute
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by Nevada Cancer Institute. Status: withdrawn.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01131247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131247.